An observational study in Brain Neoplasms, sponsored by Region Stockholm. Recruiting at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-30.
Sponsored by Region Stockholm · Observational
This study will evaluate a new type of MRI sequence designed to improve the visibility of brain metastases after gadolinium contrast injection. The purpose is to determine whether this novel "gadolinium-weighted" imaging method can detect more or smaller tumors than standard MRI techniques. Participants will undergo a routine brain MRI with contrast, followed by an additional scan using the new method. The goal is to improve diagnostic accuracy without increasing the contrast dose or scan time.
1,960 studies on the registry are indexed under Brain Neoplasms; 516 are open to participants now.
This study's planned enrollment of 100 is close to the median of 100 across 380 observational studies indexed under Brain Neoplasms.
Browse Brain Neoplasms studies →Region Stockholm is the lead sponsor of 119 studies on the registry; 70 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients referred for clinical brain MRI with contrast at a university hospital radiology department in Sweden. Participants will be adults with known or suspected brain metastases undergoing routine post-gadolinium imaging as part of their diagnostic work-up.
Exclusion Criteria:
Participants undergoing clinically indicated brain MRI with gadolinium contrast who will receive both conventional T1-weighted imaging and the novel gadolinium-weighted MRI sequence during the same scan session. The purpose is to compare lesion detection and conspicuity between the two sequences.
Diagnostic Test: Novel Gadolinium-Weighted MRI Sequence
A post-contrast MRI sequence incorporating magnetization transfer (MT) preparation and flow-nulling with motion-sensitized driven equilibrium (MSDE). The sequence is optimized to suppress background tissue and vascular signal while enhancing the visibility of gadolinium-enhancing brain metastases. It is compared to conventional T1-weighted imaging in the same exam session.
Difference in Number of Detected Gadolinium-Enhancing Brain Metastases Between the Novel Gadolinium-Weighted MRI Sequence and Conventional T1-Weighted Imaging
Time frame: At the time of gadolinium-enhanced MRI, during a single imaging session (within 1 hour of contrast administration)
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Region Stockholm